Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting

(2021) Motoyasu Kato et al.   Drug Design Development and Therapy

Progression of Idiopathic Pulmonary Fibrosis Is Associated with Silica/Silicate Inhalation

(2021) Yasuhiko Koga et al.   Environmental Science & Technology Letters

Treatment with Tumor Necrosis Factor-α Inhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients

(2020) Yoshimasa Hachisu et al.   Journal of Clinical Medicine

Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis

(2020) Yasutaka Hirasawa et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Prognostic nutritional index as a predictor of mortality in nontuberculous mycobacterial lung disease

(2020) Yoshimasa Hachisu et al.   Journal of Thoracic Disease

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study

(2020) Paolo Cameli et al.   Frontiers in Molecular Biosciences

Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study

(2020) Takafumi Koyauchi et al.   THORAX

Possible Serological Markers to Predict Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis

(2019) Yoshimasa Hachisu et al.   Medicina-Lithuania

Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels

(2019) Koga et al.   Medicina-Lithuania

Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON

(2019) Jin Woo Song et al.   RESPIROLOGY

Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment

(2019) Stefania Cerri et al.   RESPIRATORY MEDICINE

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis

(2019) Motoyasu Kato et al.   Scientific Reports

The Efficacy and Safety of Long-term Pirfenidone Therapy in Patients with Idiopathic Pulmonary Fibrosis

(2018) Kazumasa Ogawa et al.   INTERNAL MEDICINE

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

(2018) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

(2018) Bruno Crestani et al.   Lancet Respiratory Medicine

IDIOPATHIC PULMONARY FIBROSIS: Unmasking Cryptogenic Environmental Factors

(2018) Coralynn Sack et al.   EUROPEAN RESPIRATORY JOURNAL

The Role of Occupational and Environmental Exposures in the Pathogenesis of Idiopathic Pulmonary Fibrosis: A Narrative Literature Review

(2018) Samuel Trethewey et al.   Medicina-Lithuania

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

(2018) Shaney L. Barratt et al.   Frontiers in Pharmacology

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre

(2018) E. Bargagli et al.   Pulmonology

Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis

(2017) Satoshi Ikeda et al.   Scientific Reports

Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials

(2016) Arata Azuma et al.   RESPIROLOGY

Nintedanib in the treatment of idiopathic pulmonary fibrosis

(2015) Mariano E. Mazzei et al.   Therapeutic Advances in Respiratory Disease

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

(2014) Talmadge E. King et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

(2011) Paul W Noble et al.   LANCET

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

(2011) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis

(2009) Evans R. Fernández Pérez et al.   CHEST